Biological agents: a novel approach to the therapy of rheumatoid arthritis

Bibliography

• VAN DER HEIJDE DM, VAN LEEUVVEN MA, VAN RIEL PL,VAN DE PUTTE LB: Radiographic progression on radiographs of hands and feet during the first 3 years of rheumatoid arthritis measured according to Sharp's method (van der Heijde modification). J. Rheumatol (1995) 22:1792–1796.
   PubMed Web of Science ®Google Scholar
• HARRIS ED: Rheumatoid arthritis: pathophysiologyand implications for therapy. N Engl. J. Med. (1990) 322:1277–1283.
   PubMed Web of Science ®Google Scholar
• PINCUS T, CALLAGHAN LF: Taking mortality in rheuma-toid arthritis seriously - predictive markers, socioeco-nomic status and comorbidity. J. Rheumatol. (1986) 13:841–845.
   PubMed Web of Science ®Google Scholar
• WIJNANDS MJ, VAN'T HOF MA, VAN LEEUVVEN MA, VANRIJSWIJK MH, VAN DE PUTTE LB, VAN RIEL PL: Long-term second-line treatment: a prospective drug survival study. Br. J. Rheumatol. (1992) 31:253–258.
   PubMedGoogle Scholar
• FIRESTEIN GS, PAINE MM: Stromelysin and tissueinhibitor of metalloproteinases gene expression in rheumatoid arthritis synovium. Am. J. Pathol (1992) 140:1309–1314.
   PubMed Web of Science ®Google Scholar
• HANEMAAIJER R, KOOLWIJK P, LE CLERCQ L, DE VREEWJ, VAN HINSBERGH VW: Regulation of matrix metallo-proteinase expression in human vein and microvas-cular endothelial cells. Effects of tumour necrosis factor alpha, interleukin 1 and phorbol ester. Biochem. J. (1993) 296:803–809.
   Google Scholar
• SHINGU M, NAGAI Y, ISAYAMA T, NAONO T, NOBUNAGAM: The effects of cytokines on metalloproteinase inhibitors (TIMP) and collagenase production by human chondrocytes and TIMP production by synovial cells and endothelial cells. Clin. Exp. Immunol (1993) 94:145–149.
   PubMed Web of Science ®Google Scholar
• KEFFER J, PROBERT L, CAZLARIS H et al: Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J. (1991) 10:4025–4031.
   PubMed Web of Science ®Google Scholar
• ••First strong hints that TNF-a can be involved in the develop-ment of chronic arthritides.
   Google Scholar
• WILLIAMS RO, FELDMANN M, MAINI RN: Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc. Natl. Acad. Sci. USA (1992) 89:9784–9788.
   PubMed Web of Science ®Google Scholar
• ••First in vivo support of the concept that an anti-TNF-adirected therapeutic strategy could be helpful in chronic arthritis.
   Google Scholar
• WILLIAMS RO, MASON LI FELDMANN M, MAINI RN: Synergy between anti-CD4 and anti-tumor necrosis factor in the amelioration of established collagen-induced arthritis. Proc. Natl. Acad. Sci. USA (1994) 91:2762–2766.
   PubMed Web of Science ®Google Scholar
• ELLIOTT MJ, MAINI RN, FELDMANN M eta].: Treatment ofRheumatoid Arthritis with chimeric monoclonal antibodies to TNF-a. Arthritis Rheum. (1993) 36:1681–1690.
   PubMed Web of Science ®Google Scholar
• ELLIOTT MJ, MAINI RN, FELDMANN M et al: Randomised double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor a (cA2) versus placebo in Rheumatoid Arthritis. Lancet (1994) 344:1105–1110.
   PubMed Web of Science ®Google Scholar
• ••First double-blind clinical trial with cA2.
   Google Scholar
• LORENZ H-M, ANTONI C, VALERIUS T et al: In vivoblockade of TNF-alpha by i.v. infusion of a chimeric, monoclonal TNF-alpha antibody in patients with rheumatoid arthritis: short term cellular and molecular effects. J. Immunol. (1996) 156:1646–1653.
   Google Scholar
• OHSHIMA S, SAEKI Y, MIMA T et al.: Possible mechanismfor the long-term efficacy of anti-TNF alpha antibody (cA2) therapy in RA. Arthritis Rheum. (1996) 39:S242.
   Web of Science ®Google Scholar
• ELLIOTT MJ, MAINI RN, FELDMANN M et al: Repeatedtherapy with monoclonal antibody to tumor necrosis factor a (cA2) in patients with Rheumatoid Arthritis. Lancet (1994) 344:1125–1127.
   PubMed Web of Science ®Google Scholar
• LORENZ HM, GRUENKE M, HIERONYMUS T et al.: In vivoblockade of tumor necrosis factor-alpha in patients with rheumatoid arthritis: longterm effects after repeated infusion of chimeric monoclonal antibody cA2. j Rheumatol. (2000) 27:304–310.
   PubMed Web of Science ®Google Scholar
• MAINI RV, BREED VELD FC, KALDEN JR et al.: Therapeutic efficacy of multiple intravenous infusions of anti-Tumor Necrosis Factor a monoclonal antibody combined with low-dose weekly methotrexate in Rheumatoid Arthritis. Arthritis Rheum. (1998) 41:1552–1563.
   PubMed Web of Science ®Google Scholar
• ••First trial combining anti-TNF-a mAb with MTX in RA.
   Google Scholar
• CHARLES PJ, ELLIOTT MJ, FELDMANN M, MAINI RN:Development of anti dsDNA antibodies in patients with rheumatoid arthritis treated with a chimeric monoclonal antibody to TNF alpha. EULAR (1995) 24:B114.
   Google Scholar
• MAINI R, ST CLAIR EW, BREEDVELD F et al: Infliximab(chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised Phase III trial. ATTRACT Study Group. Lancet (1999) 354:1932–1939.
   PubMed Web of Science ®Google Scholar
• LIPSKY P, ST CLAIR W, FURST D et al: 54-week clinical and radiographic results from the ATTRACT trial: a Phase III study of infliximab (Remicade)in patients with active RA despite methotrexate. Arthritis Rheum. (1999) 42:S401.
   Web of Science ®Google Scholar
• ••First clinical trial showing that infliximab plus MTX can haltradiological progression in RA. Abstract text does not specify the radiological scores, actual data were given during the presentation at the meeting. Full paper will be published soon.
   Google Scholar
• RANKIN EC, CHOY EH, KASSIMOS D et al.: Thetherapeutic effect of an engineered human anti-tumor-necrosis factor alpha antibody (CDP571) in rheumatoid arthritis. Br. J. Rheumatol (1995) 34:334–342.
   PubMedGoogle Scholar
• RANKIN EC, CHOY EH, EHRENSTEIN MR et al.:Serological effects of repeated doses of an engineered human anti-TNF-alpha antibody, CDP571, in patients with rheumatoid arthritis (RA). Arthritis Rheum. (1995) 38:S279.
   Web of Science ®Google Scholar
• SANDER O, RAU R, VAN RIEL P et al.: Neutralization ofTNF by lenercept (TNER55-IgGl, Ro 45–2081) in patients with rheumatoid arthritis treated for three months: results of a European Phase II trial. Arthritis Rheum. (1996) 39:S242.
   Google Scholar
• HASLER F, VAN DE PUTTE L, BAUDIN M et al.: ChronicTNF neutralization (up to 1 year) by lenercept (TNER55-IgGl, Ro 45–2081) in patients with rheuma-toid arthritis: results of an open-label extension of a double-blind single dose Phase I study. Arthritis Rheum. (1996) 39:S243.
   Google Scholar
• FURST D, WEISMAN M, PAULUS H eta].: Neutralization ofTNF by lenercept (TNFP55-IgGl, Ro 45–2081) in patients with rheumatoid arthritis treated for three months: results of an US Phase II trial. Arthritis Rheum. (1996) 39:S243.
   Google Scholar
• MORELAND LW, BAUMGARTNER SW, SCHIFF MH et al.: Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor (p75)-Fc fusion protein. N Engl. J. Med. (1997) 337:141–147.
   PubMed Web of Science ®Google Scholar
• ••First report on successful treatment of RA with etanercept.
   Google Scholar
• MORELAND LW, SCHIFF MH, BAUMGARTNER SW et al:Etanercept therapy in rheumatoid arthritis. A random-ized, controlled trial. Ann. Intern. Med. (1999) 130:478–486.
   PubMed Web of Science ®Google Scholar
• WEINBLATT ME, KREMER JM, BANKHURST AD et al.: A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl. J. Med. (1999) 340:253–259.
   PubMed Web of Science ®Google Scholar
• ••Combination therapy of RA with etanercept with MTX issuperior to MTX alone.
   Google Scholar
• WEINBLATT ME, KREMER JM, LANGE M, BURGE DJ: Long-term savety and efficacy of combination therapy with methotrexate and etanercept. Arthritis Rheum. (1999) 42:S401.
   Web of Science ®Google Scholar
• FINCK B, MARTIN R, FLEISCHMANN R, MORELAND L, SCHIFF M, BATHON J: A Phase III trial of etanercept vs. methotrexate in early rheumatoid arthritis (Enbrel ERA trial). Arthritis Rheum. (1999) 42:S117.
   Web of Science ®Google Scholar
• SCHATTENKIRCHNER M, KRÜGER K, SANDER O, et al.: Efficacy and tolerability of weekly subcutaneous injections of the fully human anti-TNF-antibody D2E7 in patients with rheumatoid arthritis - resuts of a Phase I study. Arthritis Rheum. (1998) 41:S57 (Abstract).
   Google Scholar
• •First report on successful treatment of RA with fully human TNF-a mAb.
   Google Scholar
• VAN DE PUTTE LBA, VAN RIEL PLCM, DEN BROEDER A et al: A single dose placebo controlled Phase I study of the fully human anti-TNF-antibody D2E7 in patients with rheumatoid arthritis. Arthritis Rheum. (1998) 41:S57.
   Web of Science ®Google Scholar
• VAN DE PUTTE LBA, RAU R, BREEDVELD FC et al: Efficacy of the fully human anti-TNF antibody D2E7 in rheumatoid arthritis. Arthritis Rheum. (1999) 42:S400.
   Web of Science ®Google Scholar
• RAU R, HERBORN G, SANDER O, et al.: Long-term treatment with the fully human anti-TNF antibody D2E7 slows radiographic disease progression in rheumatoid arthritis. Arthritis Rheum. (1999) 42:S400.
   Google Scholar
• •Radiological progression is slowed, erosion progression stopped during treatment of RA patients for 12 months. Abstract only.
   Google Scholar
• JOOSTEN LA, HELSEN MM, VAN DE LOO FA, VAN DEN BERG WB: Anticytokine treatment of established Type II collagen arthritis in DBA/1 mice. A comparative study using anti-TNF alpha, anti-IL-1 alpha/beta and IL-1Ra. Arthritis Rheum. (1996) 39:797–809.
   Google Scholar
• OTANI K, NITA I, MACAULAY W, GEORGESCU HI, ROBBINS PD, EVANS CH: Suppression of antigen-induced arthritis in rabbits by ex vivo gene therapy. J. Immunol. (1996) 156:3558–3562.
   PubMed Web of Science ®Google Scholar
• LEWTHWAITE J, BLAKE SM, HARDINGHAM TE, WARDENPJ, HENDERSON B: The effect of recombinant human interleukin 1 receptor antagonist on the induction phase of antigen-induced arthritis in the rabbit. J. Rheumatol. (1994) 21:467–472.
   PubMed Web of Science ®Google Scholar
• GEIGER T, TOWBIN H, COSENTI-VARGAS A et al.: Neutralization of interleukin-1 beta activity in vivo with a monoclonal antibody alleviates collagen-induced arthritis in DBA/1 mice and prevents the associated acute-phase response. Clin. Exp. Rheumatol. (1993) 11:515–522.
   PubMed Web of Science ®Google Scholar
• CAMPION GV, LEBSACK ME, LOOKABAUGH J, GORDON G, CATALANO M: Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antago-nist in patients with rheumatoid arthritis. The IL-1Ra Arhtritis Study Group. Arthritis Rheum. (1996) 39:1092–1101.
   Google Scholar
• ••First results showing that IL- lra is superior to placebo intreatment of RA.
   Google Scholar
• BRESNIHAN B, ALVARO-GRACIA JM, COBBY M et al: Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum. (1998) 41:2196–2204.
   PubMed Web of Science ®Google Scholar
• ••First trial showing that radiological progression can beslowed down under treatment with a single immunobio-logical agent.
   Google Scholar
• WATT I, COBBY M: Recombinant human IL-1 receptor antagonist (rhIL-lra) reduces the rate of joint erosion in rheumatoid arthritis (RA). Arthritis Rheum. (1996) 39:S123.
   Google Scholar
• CUNNANE G, MADIGAN A, FITZGERALD O, BRESNIHAN B: Treatment with recombinant human interleukin-1 receptor antagonist (rhIL-lra) may reduce synovial infiltration in rheumatoid arthritis (RA). Arthritis Rheum. (1996) 39:S245.
   PubMed Web of Science ®Google Scholar
• DREVLOW B, CAPEZIO J, LOVIS R, JACOBS C, LANDAY A, POPE RM: Phase I study of recombinant human interleukin-1 receptor (RHUIL-1R) administered intra-articularly in active rheumatoid arthritis. Arthritis Rheum. (1993) 36:S39.
   PubMed Web of Science ®Google Scholar
• DREVLOW BE, LOVIS R, HAAG MA et al.: Recombinant human interleukin-1 receptor Type I in the treatment of patients with active rheumatoid arthritis. Arthritis Rheum. (1996) 39:257–265.
   PubMed Web of Science ®Google Scholar
• WENDLING D, RADACOT E, WIJDENES J: Treatment of severe Rheumatoid Arthritis by anti-interleukin 6 monoclonal antibody. J. Rheumatol. (1993) 20:259–262.
   PubMed Web of Science ®Google Scholar
• LORENZ H-M, MANGER B, KALDEN JR: Biologic agents directed against cell surface antigens as therapeutic approach to rheumatoid arthritis. EULAR J. (1995) 24:99–106.
   Google Scholar
• PANAYI GS, CHOY EHS, CONNOLLY DJA et al.: T cell hypothesis in rheumatoid arthritis (RA) tested by humanized non-depleting anti-CD4 mAb treatment I: suppression of disease activity and acute phase response. Arthritis Rheum. (1996) 39:S244.
   Google Scholar
• CHOY EHS, CONNOLLY DJA, REGAN T et al.: T cell hypothesis in rheumatoid arthritis (RA) tested by humanized non-depleting anti-CD4 mAb treatment II: clinical activity is related to pharmacodynamic effects. Arthritis Rheum. (1996) 39:S244.
   Google Scholar
• CONNOLLY DJA, CHOY EHS, RAPSON N et al.: T cell hypothesis in rheumatoid arthritis (RA) tested by humanized non-depleting anti-CD4 mAb treatment III: immunological effects. Arthritis Rheum. (1996) 39:S245.
   PubMed Web of Science ®Google Scholar
• PANAYI GS, CHOY EHS, EMERY P et al.: Repeat-cycle study of high-dose intravenous 4162W94 anti-CD4 monoclonal antibody in rheumatoid arthritis. Arthritis Rheum. (1998) 41:S56.
   Web of Science ®Google Scholar
• LEVY R, WEISMAN M, WIESENHUTTER C et al.: Results ofa placebo-controlled, multicenter trial using a primatized non-depleting, anti-CD4 monoclonal antibody in the treatment of rheumatoid arthritis. Arthritis Rheum. (1996) 39:S122.
   Google Scholar
• MAINI RN, PAULUS H, BREEDVELD FC et al: rHUIL-10 insubjects with rheumatoid arthritis: a Phase I and cytokine response study. Arthritis Rheum. (1997) 40:S224.
   Web of Science ®Google Scholar
• VAN DEN BOSCH F, RUSSELL A, CHIR B et al.: rHUIL-4 insubjects with rheumatoid arthritis: a Phase I dose escalating savety study. Arthritis Rheum. (1998) 41:S56.
   Google Scholar
• MORELAND LW, HECK LWJ, KOOPMAN WJ et al. V beta 17 T cell receptor peptide vaccination in rheumatoid arthritis: results of Phase I dose escalation study. J. Rheumatol. (1996) 23:1353–1362.
   PubMed Web of Science ®Google Scholar
• MORELAND LW, MORGAN EE, ADAMSON TC et al: T cell receptor peptide vaccination in rheumatoid arthritis. Arthritis Rheum. (1998) 41:1919–1929.
   PubMed Web of Science ®Google Scholar
• •New therapeutic principle in immunobiological treatment of RA; weak, but significant results after TCR V13 vaccination.
   Google Scholar
• MATSUMOTO AK, MORELAND LW, FOR THE IL-1RA STUDY GROUP: Results of Phase IIb rheumtoid arthritis clinical trial using T-cell receptor peptides. Arthritis Rheum. (1999) 42:S117.
   Web of Science ®Google Scholar
• JORGENSEN C, APPARAILLY F, COURET I, CANOVAS F, JACQUET C, SANY J: Interleukin-4 and interleukin-10 are chondroprotective and decrease mononuclear cell recruitment in human rheumatoid synovium in vivo. Immunology (1998) 93:518–523.
   PubMed Web of Science ®Google Scholar
• MeLLER-LADNER U, ROBERTS CR, FRANKLIN BN et al.: Human IL-1Ra gene transfer into human synovial fibroblasts is chondroprotective. J. Immunol. (1997) 158:3492–3498.
   PubMed Web of Science ®Google Scholar
• ••Clear indication that IL-1 inhibition specifically preventscartilage degradation during in vivo exposure to inflamma-tory synovial tissue.
   Google Scholar
• KAVANAUGH A, SCHAIBLE T, DEWOODY K, MARSTERSP, DITTRICH K, HARRIMAN G: Long-term follow-up of patients treated with infliximab in clinical trials. Arthritis Rheum. (1999) 42:S401.
   Google Scholar
• MORELAND LM, COHEN SB, BAUMGARTNER S, SCHIFF M,TINDALL EA, BURGE DJ: Long-term use of etanercept in patients with DMARD-refractory rheumatoid arthritis. Arthritis Rheum. (1999) 42:S401.
   Web of Science ®Google Scholar
• LANDEWE RBM, VAN DEN BORNE BEEM, MOENS H, BREEDVELD FC, HOUBEN HHML, DIJKMANS BAC: The distribution of malignant neoplasms in rheumatoid arthritis is skewed compared to the general popula-tion. Arthritis Rheum. (1999) 42:S279.
   Web of Science ®Google Scholar
• O'DELL JR, HAIRE CE, ERIKSON N et al.: Treatment ofrheumatoid arthritis with methotrexate alone, sulfasa-lazine and hydroxychloroquine, or a combination of all three medications. N. Engl. J. Med. (1996) 334:1287–1291.
   Google Scholar
• O'DELL JR: Combination DMARD therapy with hydroxychloroquine, sulfasalazine and methotrexate. Clin. Exp. Rheumatol (1999) 17:S53–58.
   Google Scholar
• O'DELL JR, LEFF R, PAULSEN G et al.: Methotrexate (M)-hydroxychloroquine (ID-sulfasalazine (S) versus M-H or M-S for rheumatoid arthritis: results of a double-blind study. Arthritis Rheum. (1999) 42:S117.
   Google Scholar
• LOVELL DJ, GIANNINI EH, REIFF A et al: Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl. J. Med. (2000) 342:763–769.
   PubMed Web of Science ®Google Scholar
• ANTONI C, DECHANT C, LORENZ H-M et al.: Successful treatment of severe psoriatic arthritis with infliximab. Arthritis Rheum. (1999) 42:S371.
   Web of Science ®Google Scholar
• MEASE P, GOFFE B, METZ J, VANDERSTOEP A: Enbrel (Etanercept) in patients with psoriatic arthritis. Arthritis Rheum. (1999) 42:S377.
   Web of Science ®Google Scholar
• STONE JH, HELLMANN DB, UHLFELDER ML et al.: Etaner-cept in Wegener's granulomatosis: interim results of an open-label trial. Arthritis Rheum. (1999) 42:S315.
   Web of Science ®Google Scholar